Loss-Leader Prices Of Anhui's Centralized Drug Bidding Winners Cause Concerns
This article was originally published in PharmAsia News
Executive SummaryThe Chinese pharma and medical community was shocked by the below-cost prices of some drugs awarded to winners of Anhui Province's 2010 centralized drug bidding
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.